Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats
Peptide T has been shown to inhibit T cell activation and cytokine production and function. Moreover, it has been reported to be a safe treatment in humans. We have studied the ability of peptide T to prevent or ameliorate EAE in Lewis rats. Peptide T was administered subcutaneously at different dos...
Saved in:
Published in | Clinical and experimental immunology Vol. 121; no. 1; pp. 151 - 156 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Science Ltd
01.07.2000
Blackwell Oxford University Press Blackwell Science Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Peptide T has been shown to inhibit T cell activation and cytokine production and function. Moreover, it has been reported to be a safe treatment in humans. We have studied the ability of peptide T to prevent or ameliorate EAE in Lewis rats. Peptide T was administered subcutaneously at different doses and phases of the disease according to several treatment protocols, but we could not observe a consistent effect of peptide T ameliorating the disease. Lymph node cell proliferation and IL‐4 and interferon‐gamma production were also studied. We conclude that peptide T neither prevents nor ameliorates EAE in Lewis rats. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 0009-9104 1365-2249 |
DOI: | 10.1046/j.1365-2249.2000.01259.x |